Gene

POT1

protection of telomeres 1

Explore in graph →CI-GENE-00020444HGNC:17284 ENSG00000128513 NCBI 25913 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
POT1 MUTATION1
(prognostic)	Chronic Lymphocytic Leukemia	Prognostic	B	Supports Poor Outcome	3	accepted	EID1590 In previously untreated patients with chronic lymphocytic leukemia, POT1 mutations (N=13) were associated with shorter overall survival than wildtype POT1 (N=148) in univariate and multivariate analys… (full text at CIViC) PMID 27226433 · Herling et al., 2016 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (22)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved22 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
The Angiosarcoma Project (Provisional, July 2020) angs_painter_2020	Angiosarcoma	Ssm	15	83	18.1%	6

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.
· Blood · 2016 · PMID 27226433 · validated civic_curation pubmed